Department of Otolaryngology, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
Department of Otolaryngology, School of Medicine, Taipei Medical University, Taipei, Taiwan.
J Imaging Inform Med. 2024 Oct;37(5):2474-2489. doi: 10.1007/s10278-024-01109-7. Epub 2024 Apr 30.
Recurrences are frequent in nasopharyngeal carcinoma (NPC) despite high remission rates with treatment, leading to considerable morbidity. This study aimed to develop a prediction model for NPC survival by harnessing both pre- and post-treatment magnetic resonance imaging (MRI) radiomics in conjunction with clinical data, focusing on 3-year progression-free survival (PFS) as the primary outcome. Our comprehensive approach involved retrospective clinical and MRI data collection of 276 eligible NPC patients from three independent hospitals (180 in the training cohort, 46 in the validation cohort, and 50 in the external cohort) who underwent MRI scans twice, once within 2 months prior to treatment and once within 10 months after treatment. From the contrast-enhanced T1-weighted images before and after treatment, 3404 radiomics features were extracted. These features were not only derived from the primary lesion but also from the adjacent lymph nodes surrounding the tumor. We conducted appropriate feature selection pipelines, followed by Cox proportional hazards models for survival analysis. Model evaluation was performed using receiver operating characteristic (ROC) analysis, the Kaplan-Meier method, and nomogram construction. Our study unveiled several crucial predictors of NPC survival, notably highlighting the synergistic combination of pre- and post-treatment data in both clinical and radiomics assessments. Our prediction model demonstrated robust performance, with an accuracy of AUCs of 0.66 (95% CI: 0.536-0.779) in the training cohort, 0.717 (95% CI: 0.536-0.883) in the testing cohort, and 0.827 (95% CI: 0.684-0.948) in validation cohort in prognosticating patient outcomes. Our study presented a novel and effective prediction model for NPC survival, leveraging both pre- and post-treatment clinical data in conjunction with MRI features. Its constructed nomogram provides potentially significant implications for NPC research, offering clinicians a valuable tool for individualized treatment planning and patient counseling.
尽管鼻咽癌(NPC)的治疗缓解率很高,但复发率仍然很高,导致相当高的发病率。本研究旨在通过结合治疗前后磁共振成像(MRI)放射组学和临床数据,开发 NPC 生存预测模型,重点关注 3 年无进展生存(PFS)作为主要结局。我们的综合方法包括从三家独立医院(180 例在训练队列中,46 例在验证队列中,50 例在外部队列中)中回顾性收集符合条件的 NPC 患者的临床和 MRI 数据,这些患者在治疗前 2 个月内和治疗后 10 个月内接受了两次 MRI 扫描。从治疗前后的增强 T1 加权图像中提取了 3404 个放射组学特征。这些特征不仅来自原发肿瘤,还来自肿瘤周围的相邻淋巴结。我们进行了适当的特征选择管道,然后进行 Cox 比例风险模型进行生存分析。使用接收者操作特征(ROC)分析、Kaplan-Meier 方法和列线图构建来评估模型。我们的研究揭示了 NPC 生存的几个关键预测因素,特别是强调了临床和放射组学评估中治疗前后数据的协同组合。我们的预测模型表现出稳健的性能,在训练队列中的准确性 AUC 为 0.66(95%CI:0.536-0.779),在测试队列中的准确性 AUC 为 0.717(95%CI:0.536-0.883),在验证队列中的准确性 AUC 为 0.827(95%CI:0.684-0.948),可预测患者结局。本研究提出了一种新的有效的 NPC 生存预测模型,该模型结合了治疗前后的临床数据和 MRI 特征。构建的列线图为 NPC 研究提供了潜在的重要意义,为临床医生提供了一种有价值的个体化治疗计划和患者咨询工具。